No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 5.000
- -0.300-5.66%
Close Jul 19 16:00 ET
- 5.010
- +0.010+0.20%
Post 19:57 ET
411.19MMarket Cap-2415P/E (TTM)
5.320High4.950Low1.81MVolume5.300Open5.300Pre Close9.10MTurnover2.36%Turnover RatioLossP/E (Static)82.24MShares11.69052wk High1.40P/B382.06MFloat Cap4.45052wk Low--Dividend TTM76.41MShs Float99.950Historical High--Div YieldTTM6.98%Amplitude4.450Historical Low5.042Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Recent Uptick Might Appease Editas Medicine, Inc. (NASDAQ:EDIT) Institutional Owners After Losing 35% Over the Past Year
Key Insights Significantly high institutional ownership implies Editas Medicine's stock price is sensitive to their trading actions 51% of the business is held by the top 13 shareholders
Express News | Editas Medicine Inc : RBC Cuts Target Price to $8 From $11
Editas Medicine (NASDAQ:EDIT) Investors Are Sitting on a Loss of 90% If They Invested Three Years Ago
Synthetic Immunology Market Report 2024 With Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
Is Editas Medicine, Inc. (EDIT) One of the Best Biotech Penny Stocks to Buy Now?
What Makes Editas Medicine, Inc. (EDIT) One of the Best Small-Cap Stocks With Highest Upside Potential?
Comments
How does the biotech ecosystem support advancements in personalized medicine & genomics? ![]()
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
• Editing Genes | $CRISPR Therapeutics(CRSP.US$ , $Intellia Therapeutics(NTLA.US$ , $Beam Therapeutics(BEAM.US$ , $Verve Therapeutics(VERV.US$ , $Editas Medicine(EDIT.US$
• Creating Therapies | $Prime Medicine(PRME.US$ , $Sana Biotechnology(SANA.US$
• Building DNA | $Twist Bioscience(TWST.US$ , $Ginkgo Bioworks(DNA.US$ , $Pacific Biosciences of California(PACB.US$ , $Illumina(ILMN.US$
• Dis...
7
$Editas Medicine(EDIT.US$
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
NEWS
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine demonstrated significant scientific advances in in vivo gene editing technologies, including lipid nanoparticle formulations for efficient delivery and guide RNA modifications to enhance editing potency.
The efficacy of AsCas12a nuclease in vivo was demonstrated by Editas Medicine, sho...
1
$Editas Medicine(EDIT.US$
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
NEWS
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
1
Despite Editas Medicine's stock price surge, its P/S ratio remains modest due to inferior revenue forecasts. Without revenue improvement, the P/S ratio will continue to limit the share price.
Analysts are divided on Editas Medicine's performance, with some optimistic and others pessimistic. The projected increase in losses next year is worrisome, despite the rise in revenue estimates. The company's revenue growth is anticipated to lag behind the broader industry, posing a potential downside.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
